We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
欧洲委员会批准Zepzelca和阿替利珠单抗联合治疗侵袭性肺癌。死亡风险降低27%。了解新治疗标准的详细信息。
